35亿！器械巨头又一全资收购

Core Viewpoint - Edwards Lifesciences has completed the acquisition of Vectorious Medical Technologies for approximately $497 million, marking a strategic shift towards remote monitoring of heart failure patients, indicating a trend in cardiovascular treatment moving from "device implantation" to "device + data management" [2][4]. Acquisition Details - The acquisition values Vectorious at $497 million, with Edwards previously acquiring 52% of the company in 2023 before completing the purchase of the remaining 48% in September 2025 [4]. - Vectorious will continue to operate as a wholly-owned subsidiary based in Tel Aviv [4]. Core Technology: V-LAP Sensor - The V-LAP sensor is implanted via minimally invasive surgery and monitors left atrial pressure in real-time, aiding in the management of heart failure [5]. - The sensor's data is uploaded daily to a dedicated mobile application, allowing doctors to track patients remotely [5]. Clinical Progress - The acquisition signifies that Edwards is completing a full chain of management from valve replacement to heart failure management [7]. Company Background and Strategic Extension - Vectorious is a pioneer in remote monitoring for heart failure, aiming to reduce hospital readmissions and improve patient quality of life [9]. - The V-LAP sensor is the first of its kind globally, enabling proactive management of heart failure through daily monitoring [9]. Strategic Logic: Phased Acquisition Path - Edwards has a history of strategic acquisitions, including Innovalve and a partnership with Affluent Medical, enhancing its position in the heart valve market [13]. - The acquisition of Vectorious represents a significant step into remote monitoring and digital health, transitioning from "device treatment" to "comprehensive disease management" [13]. - The phased approach of investing, acquiring control, and then fully integrating allows for reduced innovation risk while ensuring a foothold in new markets [13]. Industry Implications - The acquisition reflects a broader trend in cardiovascular care, moving from structural repair to active monitoring and comprehensive management [15]. - The V-LAP sensor exemplifies the integration of devices and data platforms for remote management and digital health [14]. Insights for the Chinese Market - The growing number of heart failure patients in China, combined with supportive healthcare policies, presents opportunities for local companies to explore the integration of "device + digital" solutions [16].